These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
369 related items for PubMed ID: 2884229
1. Effects of age, duration and treatment of insulin-dependent diabetes mellitus on residual beta-cell function: observations during eligibility testing for the Diabetes Control and Complications Trial (DCCT). The DCCT Research Group. J Clin Endocrinol Metab; 1987 Jul; 65(1):30-6. PubMed ID: 2884229 [Abstract] [Full Text] [Related]
2. Effect of intensive therapy on residual beta-cell function in patients with type 1 diabetes in the diabetes control and complications trial. A randomized, controlled trial. The Diabetes Control and Complications Trial Research Group. Ann Intern Med; 1998 Apr 01; 128(7):517-23. PubMed ID: 9518395 [Abstract] [Full Text] [Related]
10. Natural course of remission in IDDM during 1st yr after diagnosis. Martin S, Pawlowski B, Greulich B, Ziegler AG, Mandrup-Poulsen T, Mahon J. Diabetes Care; 1992 Jan 01; 15(1):66-74. PubMed ID: 1737543 [Abstract] [Full Text] [Related]
12. Beta-cell function and the development of diabetes-related complications in the diabetes control and complications trial. Steffes MW, Sibley S, Jackson M, Thomas W. Diabetes Care; 2003 Mar 01; 26(3):832-6. PubMed ID: 12610045 [Abstract] [Full Text] [Related]
13. The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the diabetes control and complications trial. Diabetes; 1995 Aug 01; 44(8):968-83. PubMed ID: 7622004 [Abstract] [Full Text] [Related]
14. Lipid and lipoprotein levels in patients with IDDM diabetes control and complication. Trial experience. The DCCT Research Group. Diabetes Care; 1992 Jul 01; 15(7):886-94. PubMed ID: 1516509 [Abstract] [Full Text] [Related]
15. Residual beta-cell function more than glycemic control determines abnormalities of the insulin-like growth factor system in type 1 diabetes. Hedman CA, Frystyk J, Lindström T, Chen JW, Flyvbjerg A, Ørskov H, Arnqvist HJ. J Clin Endocrinol Metab; 2004 Dec 01; 89(12):6305-9. PubMed ID: 15579794 [Abstract] [Full Text] [Related]
16. Residual beta-cell function in children with type 1 diabetes: measurement and impact on glycemic control. Daneman D, Clarson C. Clin Invest Med; 1987 Sep 01; 10(5):484-7. PubMed ID: 3315370 [Abstract] [Full Text] [Related]
18. The relevance of persistent C-peptide secretion in type 1 (insulin-dependent) diabetes mellitus to glycaemic control and diabetic complications. Winocour PH, Jeacock J, Kalsi P, Gordon C, Anderson DC. Diabetes Res Clin Pract; 1990 Apr 01; 9(1):23-35. PubMed ID: 2351037 [Abstract] [Full Text] [Related]